Embed

Academic

Authors

Axel Grothey

Axel Grothey,Mayo Clinic,Oncology,Pharmacology,Diseases

Edit

Axel Grothey

Mayo Clinic

Publications: 140 | Citations: 1932

Fields: Oncology, Pharmacology, Diseases

Collaborated with 346 co-authors from 1997 to 2011 | Cited by 6091 authors

Cumulative Annual

Sort by:

Publications (140)

BibTeX | RIS | RefWorks Download

Two or three year disease-free survival (DFS) as a primary end-point in stage III adjuvant colon cancer trials with fluoropyrimidines with or without oxaliplatin or irinotecan: Data from 12,676 patients from MOSAIC, X-ACT, PETACC-3, C-06, C-07 and C89803

, , , , , , , , , ,

Journal: European Journal of Cancer - EUR J CANCER , vol. 47, no. 7, pp. 990-996, 2011

Curable Metastatic Colorectal Cancer

Journal: Current Oncology Reports , vol. 13, no. 3, pp. 168-176, 2011

Defective Mismatch Repair As a Predictive Marker for Lack of Efficacy of Fluorouracil-Based Adjuvant Therapy in Colon Cancer (Citations: 39)

, , , , , , , , , , , http://academic.research.microsoft.com/io.ashx?type=5&id=30841305&selfId1=23348376&selfId2=0&maxNumber=12&query=

Journal: Journal of Clinical Oncology - J CLIN ONCOL , vol. 28, no. 20, pp. 3219-3226, 2010

Association Between Disease-Free Survival and Overall Survival When Survival Is Prolonged After Recurrence in Patients Receiving Cytotoxic Adjuvant Therapy for Colon Cancer: Simulations Based on the 20,800 Patient ACCENT Data Set (Citations: 6)

, , , , , , , , , , , http://academic.research.microsoft.com/io.ashx?type=5&id=30845229&selfId1=23348376&selfId2=0&maxNumber=12&query=

Journal: Journal of Clinical Oncology - J CLIN ONCOL , vol. 28, no. 3, pp. 460-465, 2010

Adjuvant Chemotherapy for Resected Stage II and III Colon Cancer: Comparison of Two Widely Used Prognostic Calculators (Citations: 5)

, , , , , , , ,

Journal: Seminars in Oncology - SEMIN ONCOL , vol. 37, no. 1, pp. 39-46, 2010

Sort by:

Citations (1932 times by 1535 publications)

Colorectal Cancer Linkage on Chromosomes 4q21, 8q13, 12q24, and 15q22

, , , , , , , , , , , http://academic.research.microsoft.com/io.ashx?type=5&id=57405161&selfId1=23348376&selfId2=0&maxNumber=12&query=

Journal: PLOS One , vol. 7, no. 5, 2012

Anti-EGFR Monoclonal Antibodies for Treatment of Colorectal Cancers: Development of Cetuximab and Panitumumab (Citations: 1)

Journal: Journal of Clinical Pharmacology - J CLIN PHARMACOL , vol. 52, no. 2, pp. 128-155, 2012

Molecular Marker Identification for Relapse Prediction in 5-FU-Based Adjuvant Chemotherapy in Gastric and Colorectal Cancers

, , , , , , , , , , , http://academic.research.microsoft.com/io.ashx?type=5&id=57407375&selfId1=23348376&selfId2=0&maxNumber=12&query=

Journal: PLOS One , vol. 7, no. 8, 2012

Fascin, a novel marker of human hepatic stellate cells, may regulate their proliferation, migration, and collagen gene expression through the FAK-PI3K-Akt pathway

, , , , , , ,

Journal: Laboratory Investigation - LAB INVEST , vol. 92, no. 1, pp. 57-71, 2012

On the Time to Conclusion of Phase II Cancer Clinical Trials and Its Application in Trial Designs

Published in 2012.

Comments

Co-authors (346)

Journals (45)

Keywords (210)

Axel Grothey,Mayo Clinic,Oncology,Pharmacology,Diseases

Publications (140)

BibTeX | RIS | RefWorks Download

Two or three year disease-free survival (DFS) as a primary end-point in stage III adjuvant colon cancer trials with fluoropyrimidines with or without oxaliplatin or irinotecan: Data from 12,676 patients from MOSAIC, X-ACT, PETACC-3, C-06, C-07 and C89803

Curable Metastatic Colorectal Cancer

Defective Mismatch Repair As a Predictive Marker for Lack of Efficacy of Fluorouracil-Based Adjuvant Therapy in Colon Cancer (Citations: 39)

Association Between Disease-Free Survival and Overall Survival When Survival Is Prolonged After Recurrence in Patients Receiving Cytotoxic Adjuvant Therapy for Colon Cancer: Simulations Based on the 20,800 Patient ACCENT Data Set (Citations: 6)

Adjuvant Chemotherapy for Resected Stage II and III Colon Cancer: Comparison of Two Widely Used Prognostic Calculators (Citations: 5)

Citations (1932 times by 1535 publications)

Colorectal Cancer Linkage on Chromosomes 4q21, 8q13, 12q24, and 15q22

Anti-EGFR Monoclonal Antibodies for Treatment of Colorectal Cancers: Development of Cetuximab and Panitumumab (Citations: 1)

Molecular Marker Identification for Relapse Prediction in 5-FU-Based Adjuvant Chemotherapy in Gastric and Colorectal Cancers

Fascin, a novel marker of human hepatic stellate cells, may regulate their proliferation, migration, and collagen gene expression through the FAK-PI3K-Akt pathway

On the Time to Conclusion of Phase II Cancer Clinical Trials and Its Application in Trial Designs


	View FAQ about top research areas and Fields of study

Axel Grothey,Mayo Clinic,Oncology,Pharmacology,Diseases

Publications (140) BibTeX | RIS | RefWorks Download

Defective Mismatch Repair As a Predictive Marker for Lack of Efficacy of Fluorouracil-Based Adjuvant Therapy in Colon Cancer (Citations: 39)

Association Between Disease-Free Survival and Overall Survival When Survival Is Prolonged After Recurrence in Patients Receiving Cytotoxic Adjuvant Therapy for Colon Cancer: Simulations Based on the 20,800 Patient ACCENT Data Set (Citations: 6)

Adjuvant Chemotherapy for Resected Stage II and III Colon Cancer: Comparison of Two Widely Used Prognostic Calculators (Citations: 5)

Anti-EGFR Monoclonal Antibodies for Treatment of Colorectal Cancers: Development of Cetuximab and Panitumumab (Citations: 1)

Publications (140)

BibTeX | RIS | RefWorks Download